NP Allies Return to NPA Main Site

Treatment overview

Ibogaine

Ibogaine is a psychoactive alkaloid that has been used in specialized clinics, often outside the United States, to interrupt substance dependence and trauma-related pathways under continuous medical supervision with cardiac monitoring. The experience is intense and typically lasts many hours, with integration support considered essential.

Overview

What It Is Ibogaine is a psychoactive alkaloid that has been used in specialized clinics (often outside the United States) to interrupt substance dependence and, in some reports, trauma-related symptoms. Administration occurs under medical supervision with continuous cardiac monitoring because of known heart-rhythm risks.

How It Works Ibogaine affects multiple neurotransmitter systems and appears capable of producing a rapid interruption of withdrawal and craving for some people, with potential effects on addiction-related learning circuits. The experience is intense; integration support afterward is considered essential. Mechanisms related to lasting change are still being studied.

Conditions - Used in specialized settings for: substance dependence (especially opioids) and, in some reports, trauma-related distress. - Note: Not FDA-approved. Serious cardiac risks require continuous monitoring. Legal status is highly restricted. This is a higher-risk option than most others listed.

How it is administered

Medically supervised sessions in specialized clinics (where legally available), with continuous cardiac monitoring. The experience is intensive and typically followed by integration support.

The NPA Treatment Database lists this treatment in connection with 1 condition record. A database relationship does not establish effectiveness, safety, or suitability for an individual.

These controlled question pages reference this treatment through stored condition relationships.

Symptoms connected in the NPA database

The current record associates this treatment with the following symptom information. This is not a claim that the treatment will improve these symptoms.

Cognition & Memory

  • concentration problems
  • Impaired control
  • memory issues related to use

Emotion & Behavior

  • continued use despite harm
  • Cravings
  • irritability
  • mood swings
  • risk-taking

Practical information

Insurance coverage

Not covered.

Cost information

High – clinic programs often $5,000–$15,000+.

Results and outcomes described in the source record

With regards to addiction, some report rapid interruption of withdrawal/cravings; long-term outcomes vary widely. For PTSD and PTSD related to TBI, reports indicate rapid interruption of symptoms and

Side effects and risks

Serious risks including cardiac arrhythmias, seizures, and death. Requires careful medical screening.

Research context in the NPA database

This section reproduces the current database's research summary and detail. Structured citation metadata has not been supplied, so it should not be read as an independently verified literature review.

Research summary

Evidence Level: Limited (and higher risk)

What the research shows: Observational reports from specialized clinics describe possible interruption of substance dependence for some people. Serious heart-rhythm risks are well documented, and the treatment is not approved in the United States.

Key takeaway: An experimental, high-risk intervention that should only be considered in carefully monitored medical settings where it is legally available.

Research detail

Overview Ibogaine is a psychoactive alkaloid derived from the African shrub Tabernanthe iboga. In certain specialized clinics (often outside the United States) it has been used to rapidly interrupt substance dependence and trauma-related pathways. Administration occurs under medical supervision with continuous cardiac monitoring because of known risks of serious heart-rhythm disturbances. The experience is intense and typically lasts many hours; integration support is considered essential.

Evidence Base and Published Work • Observational series from specialized clinics describe possible interruption of substance dependence and, in some reports, PTSD- or depression-related symptoms. • Serious cardiac-arrhythmia risks are well documented; continuous cardiac monitoring and careful medical screening are essential. • Ibogaine is not FDA-approved for any indication in the United States. Legal and regulatory status is highly restricted. • Key published work includes: – Observational series from specialized clinics. – Laboratory research on addiction-related circuits. – Reviews highlighting both potential effects and significant cardiac safety risks. – The intervention carries higher risk than most other options listed and should only be considered in carefully monitored medical settings where it is legally available.

Outcomes in observational reports include possible interruption of substance dependence for some people. Serious heart-rhythm risks are well documented. The treatment is experimental and high-risk.

Questions to ask a provider

1. Is ibogaine being considered in a medically supervised, legal setting with continuous cardiac monitoring? 2. What pre-treatment screening (especially cardiac) is required, and what are the serious risks? 3. What substance-use or trauma-related goals is the treatment intended to address, and what outcomes are reported? 4. What integration support is provided after the session? 5. What is the legal status of this treatment in the location where it would be delivered, and what are the total costs?

Explore the interactive Treatment Database

Continue to compare educational treatment information in the interactive database. The standard disclaimer acknowledgement is required before the database opens.

Explore treatment information in the database

Educational information disclaimer

The information provided in this app is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment, and should not be relied upon as a substitute for professional medical care.

Treatments, therapies, and interventions described here may not be appropriate for every person or condition. Evidence levels, availability, costs, insurance coverage, and risks can vary. Nothing in this app constitutes a recommendation that you start, stop, or change any treatment.

Always consult your physician, neurologist, or other qualified healthcare provider before beginning any new therapy, device, program, or intervention, and before making decisions about your care. Seek prompt medical attention for any urgent or emergency symptoms. By using this app, you acknowledge that NP Allies and its contributors are not responsible for any decisions you make based on the information provided, or for any outcomes that result from those decisions.